Equity Profile

DHR

Danaher Corporation

Health CareLife Sciences Tools & Services$129.3B

Jul21Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Danaher Corporation (DHR) operates in the health care sector, focusing on life sciences tools and services. The company plays a crucial role in providing innovative solutions for diagnostics, biopharmaceutical manufacturing, and water quality, which are essential for health and safety.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DHR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+7.56%

Avg Stock Reaction

-0.36%

Last Quarter Recap

In Q1 2026, Danaher reported an EPS of $2.06, beating estimates by 5.91%. The stock reacted slightly negatively the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Focus on innovation in life sciences tools.
Commitment to improving operational efficiencies.
Plans to expand into emerging markets.

Expectations

Wall Street Expectations

Overall expectations for Danaher's upcoming earnings are cautious, given the lack of analyst estimates and mixed reactions to previous earnings reports.

Bull Case

If Danaher continues its trend of beating EPS estimates, it could signal strong operational performance and growth, boosting investor confidence.

Bear Case

Concerns about potential revenue stagnation or increased costs could lead to a disappointing earnings report, negatively impacting the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026, and how does it compare to previous quarters?

The EPS figure will be a critical indicator of Danaher's profitability and could influence investor sentiment significantly.

How is Danaher addressing cost pressures and supply chain challenges?

Understanding management's strategy for managing costs will be crucial for assessing future profitability and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Danaher's ability to manage costs effectively, especially given its historical EPS beat rate of 88%.

Supporting Evidence

Danaher has consistently outperformed EPS estimates, suggesting strong operational execution.

The options market is pricing for a larger move than historical averages, indicating potential for a positive surprise.

Management's focus on innovation and efficiency could lead to better-than-expected results.

Key Risk

If EPS comes in below $1.95, it could validate bearish sentiment and lead to a significant sell-off.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Danaher's ability to maintain profitability amid potential cost pressures and competition.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.95 would raise concerns about profitability and operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±7.99%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±8.0% while DHR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

29.5%

Calls (164K)P/C Ratio: 0.32Puts (289K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Danaher beats expectations, history suggests a potential stock increase of around +0.98%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.

Miss

A miss could lead to a decline of around -9.73%, reflecting investor disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-TXJulie JohnsonRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost management strategies and their impact on margins.
2Insights into revenue growth in key segments like diagnostics and biopharma.
3Management's outlook on emerging market opportunities.
4Details on new product innovations and their expected market impact.
5Comments on supply chain challenges and how they are being addressed.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ICICI Bank Limited

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DHR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+7.56%

Avg Stock Reaction

-0.36%

Last Quarter Recap

In Q1 2026, Danaher reported an EPS of $2.06, beating estimates by 5.91%. The stock reacted slightly negatively the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Focus on innovation in life sciences tools.
Commitment to improving operational efficiencies.
Plans to expand into emerging markets.

Expectations

Wall Street Expectations

Overall expectations for Danaher's upcoming earnings are cautious, given the lack of analyst estimates and mixed reactions to previous earnings reports.

Bull Case

If Danaher continues its trend of beating EPS estimates, it could signal strong operational performance and growth, boosting investor confidence.

Bear Case

Concerns about potential revenue stagnation or increased costs could lead to a disappointing earnings report, negatively impacting the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026, and how does it compare to previous quarters?

The EPS figure will be a critical indicator of Danaher's profitability and could influence investor sentiment significantly.

How is Danaher addressing cost pressures and supply chain challenges?

Understanding management's strategy for managing costs will be crucial for assessing future profitability and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Danaher's ability to manage costs effectively, especially given its historical EPS beat rate of 88%.

Supporting Evidence

Danaher has consistently outperformed EPS estimates, suggesting strong operational execution.

The options market is pricing for a larger move than historical averages, indicating potential for a positive surprise.

Management's focus on innovation and efficiency could lead to better-than-expected results.

Key Risk

If EPS comes in below $1.95, it could validate bearish sentiment and lead to a significant sell-off.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Danaher's ability to maintain profitability amid potential cost pressures and competition.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and growth.

Bear Confirmed If

An EPS below $1.95 would raise concerns about profitability and operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±7.99%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±8.0% while DHR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

29.5%

Calls (164K)P/C Ratio: 0.32Puts (289K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Danaher beats expectations, history suggests a potential stock increase of around +0.98%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.

Miss

A miss could lead to a decline of around -9.73%, reflecting investor disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-TXJulie JohnsonRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost management strategies and their impact on margins.
2Insights into revenue growth in key segments like diagnostics and biopharma.
3Management's outlook on emerging market opportunities.
4Details on new product innovations and their expected market impact.
5Comments on supply chain challenges and how they are being addressed.